MISSISSAUGA, Ontario, Oct. 6 /PRNewswire/ -- Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH), has authored a cover story for this month's Medical Device & Diagnostic Industry Magazine (MD+DI) which addresses improvements in diagnostic times using point-of-care technology. In the article, titled "Improving Diagnosis Times with New Point-of-Care Technology," Dr. Gawad reviews the in-vitro diagnostics market and the growth of point-of-care testing.
In addition to reviewing other point-of-care devices, Dr. Gawad describes the operation of the QL Care Analyzer™, CardioGenics' point-of-care immunoassay platform that will allow a heart attack diagnosis to be made in as little as 15 minutes vs. the national average of 2.8 hours required for test results from a central lab. CardioGenics expects to submit to the FDA a 510K application for the QL Care Analyzer™ (and its first cardiac test, Troponin-I) during Q1 2011 and to have both commercialized by Q2 2011.
The article can be accessed online at:
About Medical Device & Diagnostics Industry
Medical Device & Diagnostic Industryis a leading monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnostic products. The goal of MD&DI is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. MD&DI is published 12 times each year, along with two additional issues of its Guide to Outsourcing supplement.